Great Scientists Are Set Up to Fail as Leaders.

One Idea Worth Acting On.

A brilliant clinical expert is promoted to lead a critical oncology development team.

Six months later the strategy is stalled, morale is collapsing, and the program is delayed.

The organization blames the leader.

In reality the organization failed the expert.

It promoted the wrong person into the wrong role — and called it recognition.

What's Actually Happening

In oncology drug development, people management has become the default reward for scientific excellence. Perform well as a researcher, physician, or clinical scientist and the path forward almost always leads to team leadership.

But doctors are trained to diagnose and decide. Scientists are trained to hypothesize and experiment. Pharmacists are trained to optimize and monitor. None of those training paths involves managing twelve people across four functions on a global drug development program.

Heather Smith, Head of Talent and Workforce Innovation at Daiichi Sankyo and contributor to Voices of Oncology, describes the pattern precisely: organizations place brilliant individual contributors into leadership positions without equipping them to succeed — then wonder why execution breaks down.

The issue is not intelligence. It is the assumption that scientific mastery automatically translates into leadership capability. It does not. They are different skills. Both can be developed. Neither comes with the other.

Why This Matters

Oncology drug development is a team sport. A therapy moves from discovery to approval through dozens of cross-functional handoffs, each one dependent on a leader who can align people, manage conflict, develop talent, and hold a team together under pressure.

When the person in that role was promoted for their scientific expertise and received no preparation for those responsibilities, the program pays for it.

And the organization loses twice. It loses a highly effective scientific contributor — the role the person was actually great at — and it loses a functioning development team at the same time.

Where It Breaks in the Real World

Heather Smith describes a highly respected clinical specialist promoted into a role that combined scientific strategy with people management. The specialist had deep therapeutic expertise. The transition still failed.

He did not enjoy managing people. His strength and his interest were in the science — in shaping clinical strategy, engaging Key Opinion Leaders, influencing development direction. The management responsibilities drained him. The team felt it.

When the organization finally shifted him into an advanced individual contributor role focused on disease strategy and KOL engagement, both he and the team began to thrive.

The problem was never his capability. It was the role he was put in and the assumption that he wanted it.

What Needs to Change

The industry needs two career tracks that carry equal prestige, compensation, and organizational standing — one for scientific and technical mastery, one for people leadership. Right now, management is the only visible path upward. That structure forces the wrong people into the wrong roles and deprives organizations of the scientific depth they need.

And when scientific experts do move into leadership, the development cannot start after the promotion. It has to start before. Feedback delivery, conflict management, cross-functional alignment, coaching — these are learnable skills. But they take time and they require deliberate investment.

The Bottom Line

You cannot cure cancer with broken teams.

Promoting brilliant scientists into leadership without equipping them to lead is not a talent strategy. It is an execution risk — one that costs programs, people, and patients.

Add Your Voice — Where are you seeing this? What's working — and what's not?